SC411
Pre-clinical- Indications
- Sickle cell disease
Company intelligence / Profile preview
Accu-Break Pharmaceuticals
Hollywood, Florida, United Statesaccubreak.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
The company has developed proprietary tablet technologies that enable precise tablet splitting for dose flexibility
- Modalities
- Small molecules (tablet formulations)
- Industry
- Drug Discovery Services
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Midas Pharma GmbH (European cooperation agreement)
Beyond the preview
Go deeper on Accu-Break Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Accu-Break Pharmaceuticals.